Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Yi Feng (NPI 1639179229)

Field	Value
Entity Type	Individual
Organization	Yi Feng
Address	7650 Dannaher Dr Ste 100
City	Powell
State	TN
ZIP	37849
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 26, 2005

Payer Source	Total Paid
Medicare	$4M
Medicaid	$0

Key Findings

This provider’s lifetime revenue profile is concentrated entirely in Medicare ($4M total Medicare revenue) with no Medicaid billing on file, making the observable payer mix effectively single-payer Medicare in our dataset. Analysts should treat Medicaid-level comparisons as not applicable for this NPI because there is no Medicaid activity to evaluate.

Revenue concentration is extreme: the precomputed top-3 codes account for 64.5% of this provider’s total Medicare revenue, driven primarily by J9271 (39.9%), J9144 (13.7%), and J0897 (11.0%). This indicates a small set of injectable biologics dominates overall receipts and should be the focus of utilization or contract review.

The code mix signals an infusion-centered hematology/oncology practice: J9271 (pembrolizumab), J9144 (daratumumab), and J0897 (denosumab) are all high-revenue injectable biologics and are complemented by chemotherapy administration codes (e.g., 96413, 96365) and supportive care agents (e.g., J2506, J0185). Together these codes imply the operation is built around on-site drug administration and associated chair/infusion services rather than office-only consults.

On national competitive standing, the provider shows notable top-tier volume for several oncology drugs: J9271 ranks #64 of 1841 providers nationally (96th percentile; notably above typical national volume) while J0897 ranks #207 of 10057 providers nationally (98th percentile; notably above typical national volume). By contrast, J9144 ranks #117 of 615 providers nationally (81th percentile; typical, unremarkable volume), indicating leadership in some drug lines but more typical participation in others.

There are multiple statistical outliers in the Medicare activity mix: J2506 ranks #5 of 586 providers nationally (99th percentile; extreme outlier) and 96372 ranks in the 100th percentile (extreme outlier), while 99214 also ranks in the 99th percentile (extreme outlier). These extreme outlier labels indicate unusually high volumes of certain supportive-care injections and E/M visit activity relative to national peers, which has operational and cost implications for payers.

Although biologic drug administration drives most revenue, the provider also reports meaningful non-drug services including E/M visits (99214, 99213, 99215), chemotherapy administration (96413, 96365, 96367, 96417), and lab testing (85025, 80053, 82728). This mix shows an integrated infusion clinic model where procedural and diagnostic services accompany high-cost drugs, so case-level utilization reviews should include both drug and non-drug billing lines.

The provider’s NPI has been enumerated since 2005-07-26 (~21 years ago), indicating a long-tenured practice entity in the market. Tenure supports a stable referral and operational history, which can contextualize high cumulative Medicare volumes when comparing newer entrants.

For payers and network managers, the concentration in a few high-cost biologics (notably J9271 as the single largest revenue driver) means contracting and utilization management focused on those agents will capture the majority of financial exposure. Coupled with an absence of Medicaid activity, contracting decisions based on Medicare experience will likely reflect the provider’s full reported commercial/Medicare infusion footprint in this dataset.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

80 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	34,800	$40	$1.5M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	13,500	$40	$513K
J0897	Injection, denosumab, 1 mg	22,860	$20	$411.5K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	10,850	$40	$390.6K
J1437	Injection, ferric derisomaltose, 10 mg	8,500	$20	$144.5K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1,690	$80	$133.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,310	$90	$115.2K
J3111	Injection, romosozumab-aqqg, 1 mg	10,920	$10	$87.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	860	$100	$81.5K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	38,900	$1	$77.8K

Showing 1–10 of 80

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 80 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Yi Feng — 14 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

80 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	50	17,400	$40	$776.1K
J9144	10	20	10,080	$40	$466.3K
J3111	17	20	15,540	$10	$256.9K
J1569	4	30	3,030	$40	$175.2K
J1437	4	20	3,700	$20	$86.3K
J0897	4	240	2,940	$20	$85K
J0881	10	70	19,050	$1	$54.4K
88185	15	30	690	$20	$51.2K
J2506	1	40	430	$80	$46.7K
J0185	2	10	17,880	$1	$23.9K

Showing 1–10 of 80

Related Providers

Other providers that share a Tax Identification Number (TIN) with Yi Feng, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mitchell Martin	TN	Hematology & Oncology Physician	$4.7M	$0
Ross Kerns	TN	Hematology & Oncology Physician	$4.5M	$0
Daniel Ibach	TN	Hematology & Oncology Physician	$4.3M	$0
Tennessee Cancer Specialists PLLC	TN	Hematology & Oncology Physician	$0	$2.7M
Dharmen Patel	TN	Hematology & Oncology Physician	$901.9K	$0
Tracy Dobbs	TN	Medical Oncology Physician	$853.5K	$0
Richard Lee	TN	Hematology & Oncology Physician	$643K	$0
Robert Schumaker	TN	Hematology & Oncology Physician	$587.3K	$0
Anil Tumkur	TN	Hematology & Oncology Physician	$491.1K	$24.3K
Saji Eapen	TN	Hematology & Oncology Physician	$487.3K	$0

Nearby Providers

Other providers in the same ZIP code as Yi Feng, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Metro Knoxville Hma LLC	TN	General Acute Care Hospital	$0	$28.7M
App Of East Tennessee Ed PLLC	TN	Emergency Medicine Physician	$0	$2.3M
Eye Surgery Center Of Knoxville, LLC	TN	Ambulatory Surgical Clinic/Center	$1M	$188.4K
Kevin Gallaher	TN	Ophthalmology Physician	$374.3K	$0
Tec North, LLC	TN	Ambulatory Surgical Clinic/Center	$366.6K	$0
Lee Congleton	TN	Urology Physician	$326.1K	$0
Christopher Ramsey	TN	Urology Physician	$299K	$0
Sean Delair	TN	Urology Physician	$208.9K	$0
Jared Spoons	TN	Internal Medicine Physician	$187.9K	$0
Rashmi Hottigoudar	TN	Clinical Cardiac Electrophysiology Physician	$178.3K	$0

Yi Feng — Billing Profile & Reimbursement Data

Sign up for Yi Feng — Billing Profile & Reimbursement Data policy alerts

Yi Feng — Billing Profile & Reimbursement Data

Sign up for Yi Feng — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References